Inpran-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30mg and Pantoprazole 40mg, designed for the management of gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and discomfort associated with delayed gastric emptying and gastroparesis. Pantoprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing effective relief from acid-related conditions such as gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The synergistic action of these two agents in Inpran-DSR Capsule addresses both motility and acid secretion abnormalities, making it suitable for patients with concomitant motility disorders and acid hypersecretion. The capsule is typically administered orally once daily, preferably before meals, under medical supervision. Caution is advised in patients with known hypersensitivity to either component, underlying cardiac conditions, or hepatic impairment. Regular monitoring and adherence to prescribed dosage are essential to minimize potential adverse effects and ensure therapeutic efficacy. Inpran-DSR Capsule should be used as part of a comprehensive treatment plan tailored to individual patient needs.